Israel's Growth Hormone Treatment: Criteria, Costs, and Emotional Toll
Thousands of children in Israel receive daily growth hormone injections to address significant height differences, aiming to improve social integration and self-confidence. Strict Ministry of Health criteria, a shortage of specialists, and potential health risks create challenges in accessing the treatment, which is subsidized for specific medical conditions. While the treatment can significantly increase a child's height, parental frustration over strict eligibility cutoffs is common, and experts stress the importance of emotional support for children who do not qualify.
הידיעה ב-6 שורות · תקציר של baba
- Thousands of Israeli children receive growth hormone treatment for significant height differences.
- Treatment eligibility in Israel is based on strict height criteria and medical necessity.
- A shortage of pediatric endocrinologists leads to long waiting times for treatment.
- Subsidized treatment is available for specific conditions, with partial costs for others.
- Parental frustration is high over strict height cutoffs for treatment eligibility.
- Theoretical health risks, though unproven, influence the cautious approach to treatment.
Thousands of children in Israel who are significantly shorter than their peers are eligible for growth hormone treatment, a daily injection aimed at helping them reach a more typical height. While these children are not ill, their stature can lead to social difficulties and impact self-confidence. The treatment, which mimics the body's natural growth hormone, stimulates growth plates in long bones, increasing height. For children like Ziv, a 7-year-old who was significantly shorter than classmates, the treatment has led to noticeable growth, increasing her annual growth rate from about 4-4.5 cm to 6.5 cm. Another child, Adam, who began treatment at age six, described the social challenges of being shorter, including being called names and feeling isolated.
The path to treatment in Israel involves strict criteria set by the Ministry of Health and a bottleneck of approximately 70 pediatric endocrinologists, leading to long waiting times. Public health funds cover the treatment for children with specific conditions, including those whose bodies do not produce growth hormone, were born with very low birth weight, or have rare syndromes like Turner and Noonan. Children who do produce the hormone may still qualify if their projected adult height is below 1.60 meters for boys and 1.50 meters for girls. For those with supplementary health plans, the cost can be around 400 shekels. However, the strict height cutoffs, such as 1.60 meters versus 1.61 meters, cause significant parental frustration.
Medical professionals acknowledge the emotional distress caused by these limitations, noting that setting any boundary will inevitably leave some children feeling excluded. A theoretical, though unproven, concern about increased future cancer risk influences the cautious approach to treatment for children who are otherwise healthy and projected to reach a height considered within the lower end of normal. Other potential risks include increased intracranial pressure, effects on blood sugar levels, and exacerbation of scoliosis. Experts emphasize that for children not meeting the criteria, parental love and support are crucial for their well-being and healthy development, and they debunk myths about supplements or exercise aiding growth.
מוזכרים
לא אותו אירוע: ידיעות אחרות שחולקות עם הידיעה הזו אנשים, מקומות או נושא. רקע, תגובות והמשכים.
